The clinical entities of IPEX and APS1 caused by the mutations of FOXP3 and AIRE, respectively, are likely to be the first of a string of new primary monogenic diseases that can be used for discovery of immune regulatory mechanisms and targeted interventions. The gene discussed is FOXP3; the disease is autoimmune polyendocrine syndrome type 1.